2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
107
Carcinoma, Renal Cell
74
Neoplasm Metastasis
48
Neoplasms
37
Neuroendocrine Tumors
35
Kidney Neoplasms
27
Recurrence
19
Tuberous Sclerosis
18
Carcinoma, Non-Small-Cell Lung
17
Prostatic Neoplasms
16
Triple Negative Breast Neoplasms
15
Lymphoma
15
Lymphoma, Mantle-Cell
14
Lymphoma, Large B-Cell, Diffuse
14
Head and Neck Neoplasms
14
Glioblastoma
14
Carcinoma, Hepatocellular
14
Colorectal Neoplasms
13
Stomach Neoplasms
12
Lung Neoplasms
12
Leukemia, Lymphocytic, Chronic, B-Cell
12
Hodgkin Disease
12
Brain Neoplasms
12
Sarcoma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Pancreatic Neoplasms
11
Glioma
11
Waldenstrom Macroglobulinemia
10
Lymphoma, Follicular
10
Carcinoma, Neuroendocrine
10
Interventions
Blood Specimen Collection
8
Magnetic Resonance Spectroscopy
5
Pentoxifylline
4
Liver Transplantation
4
Tenofovir
3
Specimen Handling
3
High-Energy Shock Waves
3
Tocopherols
2
Sorafenib
2
Simvastatin
2
Low-Level Light Therapy
2
Gemcitabine
2
tremelimumab
1
sonidegib
1
sofosbuvir-velpatasvir drug combination
1
ruxolitinib
1
peginterferon alfa-2a
1
navitoclax
1
maltodextrin
1
hepatitis B hyperimmune globulin
1
esmolol
1
epigallocatechin gallate
1
durvalumab
1
contrast agent BR1
1
bavituximab
1
atezolizumab
1
apixaban
1
alpha-Tocopherol
1
adefovir dipivoxil
1
Viusid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fibrosis
×
Everolimus
×
Clear all
NCT02134899
2018-12-10
EVERKYSTE
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
3 enrolled